U.S. surgeons have successfully tested a kidney transplant in a human patient


টার Reuters surgical team examines the pig’s kidney for any signs of hyperacute rejection, as the organ was implanted outside the body and to allow observation and tissue sampling during the 54-hour study. Joe Carrotta.


Written by Nancy Lapid

NEW YORK (Reuters) – For the first time, a pig’s kidney has been transplanted into a human without being immediately rejected by the recipient’s immune system, a potentially big breakthrough that could ultimately help overcome an extreme shortage of human organs for transplantation.

The procedure, performed at NYU Langone Health in New York City, involved the use of a pig whose genes were altered so that it no longer had a molecule in its tissue that was known to reject almost immediately.

The researcher told Reuters the recipient was a dead brain patient with symptoms of kidney dysfunction, whose life had been agreed to a family test before being hired.

For three days, the new kidney was attached to her blood vessels and maintained outside her body, giving researchers access to it.

The results of kidney transplant work are “quite normal,” said transplant surgeon Dr. Robert Montgomery, who led the study.

The kidney did “the amount of urine you would expect” from a transplanted human kidney, he said, and there is no evidence of strong, initial rejection when intact pig kidneys are transplanted into non-human primates.

The recipient’s abnormal creatinine levels – an indicator of impaired kidney function – return to normal after the transplant, Montgomery said.

According to the United Network for Organ Sharing, there are currently about 107,000 people waiting for organ transplants in the United States, of which more than 20,000 are waiting for kidneys. Kidneys wait for an average of three to five years.

Researchers have been working for decades on the possibility of using animal organs for transplants, but have become restless about how to prevent immediate rejection by the human body.

Montgomery’s team theorized that throwing pig genes for a carbohydrate that triggers rejection – a sugar molecule, or glycan, called alpha-gal – would prevent the problem.

The genetically modified pig, Dal Galsafe, was developed by the United Therapeutics (NASDAQ 🙂 Corp.’s Revival Unit. It was approved by the US Food and Drug Administration in December 2020, for use as a food for people with meat allergies and as a potential source of human treatment.

The agency said medical products made from pigs would still require specific FDA approval before they could be used in humans.

Other researchers are considering whether Galsafe pigs could be the source of everything for human patients, from heart valves to skin grafts.

The NYU Kidney Transplant Examination will pave the way for the examination of patients with end-stage kidney failure, possibly in the next year or two, Montgomery said, adding that he himself is a heart transplant recipient. These tests can test the procedure as a short-term solution for critically ill patients until the human kidney is found, or as a permanent pen.

Montgomery said the current test involved only one transplant and the kidney was left for only three days, so any future test could uncover new obstacles that need to be overcome. Participants will most likely have less difficulty receiving human kidneys and patients with poor prognosis in dialysis.

“For many people, the mortality rate is as high as for some cancers, and we don’t think twice about using new drugs and new tests (in the case of cancer patients) when it can give them a few months, much more in life,” Montgomery said.

Researchers working with medical ethicists, legal and religious experts tested the concept before asking a family for temporary admission of a brain dead patient, Montgomery said.

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button